Abstract 3516: Discovery of novel SHMT small molecule inhibitors for cancer treatment
Autor: | Agnieszka Przybylowicz, Marta Sowinska, Krzysztof Brzózka, Agnieszka Adamus, Pawel Guzik, Marcin Król, Urszula Kulesza, Przemyslaw Golik, Mateusz Nowak, Tomasz Rzymski, Karolina Gluza, Justyna Wujkowska, Nicolas Boutard, Piotr Kowalczyk, Magdalena Sieprawska-Lupa, David J. Schultz, Anna Wrobel, Karolina Pyziak, Agnieszka Sroka-Porada, Magdalena Zastawna, Anna Bartosik, Agnieszka Dreas, Faustyna Iwanska |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Cancer Research Chemistry Cell Cancer medicine.disease Serine 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Pemetrexed medicine.anatomical_structure Oncology Downregulation and upregulation 030220 oncology & carcinogenesis Serine hydroxymethyltransferase Glycine Cancer cell medicine Cancer research medicine.drug |
Zdroj: | Cancer Research. 78:3516-3516 |
ISSN: | 1538-7445 0008-5472 |
Popis: | Over-activation of the serine synthesis pathway, upregulation of SHMT2 has been described in over 20% of solid tumors (e.g. breast, lung, colorectal cancers). Such cancer cells are highly dependent on serine. Serine hydroxymethyltransferase (SHMT) plays a key role in a so-called one-carbon pathway, a group of biochemical reactions involved in amino acid metabolism. SHMT catalyzes the conversion of serine to glycine and also plays a role in the folate (vitamin B9) cycle. Antagonists of folate metabolism or antifolates are an established chemotherapy in certain cancers. Folate antagonism disrupts cell division, DNA/RNA synthesis and protein synthesis. Pemetrexed (for non-small cell lung carcinoma, mesothelioma) and methotreaxate (for autoimmune conditions like rheumatoid arthritis and certain cancers) are two well established and effective antifolates. The main drawback with antifolates in cancer treatment, however, is the development of resistance. In this study we report development of a series of small molecule SHMT1/2 inhibitors. Synthetized compounds exert potency in SHMT1/2 biochemical assay as well as in cellular assay (measured by the C13 serine to glycine conversion) with the low nanomolar range. Therapeutic effect of the compounds was investigated in the panel of cancer cell lines with different genetic background as well as with different SHMT2 levels. We identified several cell lines in which tested compounds inhibited cancer cell grow with nM GI50 values. Taken together, presented data supports our rationale for using SHMT1/2 inhibitors as a novel and interesting approach for the cancer therapy. Citation Format: Anna Bartosik, Pawel Guzik, Marta Sowinska, Karolina Gluza, Marcin Krol, Anna Wrobel, Agnieszka Dreas, Faustyna Iwanska, Magdalena Zastawna, Urszula Kulesza, Nicolas Boutard, David Schultz, Justyna Wujkowska, Karolina Pyziak, Agnieszka Sroka-Porada, Agnieszka Przybylowicz, Agnieszka Adamus, Magdalena Sieprawska-Lupa, Przemyslaw Golik, Piotr Kowalczyk, Krzysztof Brzozka, Tomasz Rzymski, Mateusz Nowak. Discovery of novel SHMT small molecule inhibitors for cancer treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3516. |
Databáze: | OpenAIRE |
Externí odkaz: |